Rising metabolic score for insulin resistance (METS-IR) levels strongly correlate with major cardiovascular events (MACE) and ...

In advanced non–small cell lung cancer (NSCLC), discontinuing immunotherapy after 2 years can maintain durable responses ...

Making treatment for non–small cell lung cancer (NSCLC) accessible to a wide range of the population can help to improve ...

The humanized IgG4 monoclonal antibody was first approved for myasthenia gravis in the US in 2023, with approvals in Japan ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

Patients with myeloproliferative neoplasms (MPNs) appear to be at a higher risk of heart failure and pulmonary hypertension, ...

Telomere length can be used in the diagnosis of interstitial lung diseases like idiopathic pulmonary fibrosis, but it likely ...

Patients with alopecia universalis and alopecia totalis are at a particularly high risk of cardiovascular disease, a new ...

James Chalmers, MBChB, PhD, highlights the reassuring safety and tolerability profile of brensocatib in patients with non–cystic fibrosis bronchiectasis.

Panelists discuss the challenges of biologic access in hidradenitis suppurativa due to utilization management policies like step therapy, emphasizing the need for patient education, strategic planning ...

US adults who were displaced and never returned home due to a natural disaster had the highest odds of developing depression or anxiety.

A new study finds that drugmakers’ use of overlapping patents delayed generic entry for 4 top-selling drugs, driving billions in excess spending.